LOVFF (Cannara Biotech) ROCE %: 9.15% (As of Feb. 2026)


LOVFF Cannara Biotech Inc LOVFF
83 GF Score
Price $1.21
GF Value $1.15
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cannara Biotech ROCE %?

Cannara Biotech LOVFF +5.52% 83 ROCE % is 9.15% as of Feb. 2026. GuruFocus rates LOVFF with a GF Score™ of 83/100 and a GF Value™ of $1.15 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cannara Biotech's annualized ROCE % for the quarter that ended in Feb. 2026 was 9.15%.

Cannara Biotech  (OTCPK:LOVFF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cannara Biotech ROCE % Related Terms

Cannara Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Cannara Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech ROCE % Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
ROCE %
Get a 7-Day Free Trial 0.27 5.07 9.60 7.48 16.59

Cannara Biotech Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.91 20.63 15.89 7.59 9.15
LOVFF
83GF Score
Cannara Biotech Inc LOVFF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cannara Biotech ROCE % Calculation

Cannara Biotech's annualized ROCE % for the fiscal year that ended in Aug. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=15.845/( ( (113.306 - 19.774) + (122.234 - 24.787) )/ 2 )
=15.845/( (93.532+97.447)/ 2 )
=15.845/95.4895
=16.59 %

Cannara Biotech's ROCE % of for the quarter that ended in Feb. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Feb. 2026 )  (Q: Nov. 2025 )(Q: Feb. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Feb. 2026 )  (Q: Nov. 2025 )(Q: Feb. 2026 )
=9.724/( ( (123.679 - 22.408) + (133.212 - 21.824) )/ 2 )
=9.724/( ( 101.271 + 111.388 )/ 2 )
=9.724/106.3295
=9.15 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 9.15% mean?
Cannara Biotech (LOVFF) has a ROCE % of 9.15% as of Feb. 2026.
Is Cannara Biotech's ROCE % too high?
Cannara Biotech's current ROCE % is 9.15%. The Drug Manufacturers industry median ROCE % is 7.01. Cannara Biotech's value of 9.15% is 30.5% above this industry median. Overall, Cannara Biotech has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's ROCE % compare to ZTS and UTHR?
Cannara Biotech's ROCE % of 9.15% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. Cannara Biotech's value of 9.15% is 30.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current ROCE % of 9.15% is 30.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current ROCE % is 9.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.15, compared to a current price of $1.21 — trading 5.5% above its estimated fair value. The current ROCE % is 9.15% and 30.5% above the Drug Manufacturers industry median of 7.01. Cannara Biotech's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current ROCE % is 9.15% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (LOVFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued. The current stock price of $1.21 is trading 5.5% above its estimated GF Value™ of $1.15. GuruFocus considers Cannara Biotech to be Fairly Valued.

Key valuation signals for LOVFF:

  • ROCE %: 9.15%
  • GF Value™: $1.15 vs. price of $1.21 (5.5% above fair value)
  • GF Score™: 83/100 with 4 warning signs
  • Industry Position: 30.5% above the Drug Manufacturers median

No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cannara Biotech Business Description

Other Exchanges 8CB0:GermanyLOVE:Canada
Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
83GF Score

Get the complete analysis for LOVFF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.21
Price
$1.15
GF Value